June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Visual Field Outcomes from LiGHT: Laser in Glaucoma and Ocular Hypertension, a multicentre, randomised controlled trial.
Author Affiliations & Notes
  • David Michael Wright
    Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom
    Health Data Research UK, United Kingdom
  • Evgenia Konstantakopoulou
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
    Division of Optics and Optometry, University of West Attica, Greece
  • Giovanni Montesano
    Optometry and Visual Science, School of Health Science, City, University of London, London, United Kingdom
  • Neil Nathwani
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Anurag Garg
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • David F Garway-Heath
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
    Institute of Ophthalmology, University College London, London, United Kingdom
  • David P. Crabb
    Optometry and Visual Science, School of Health Science, City, University of London, London, United Kingdom
  • Gus Gazzard
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
    Institute of Ophthalmology, University College London, London, United Kingdom
  • Footnotes
    Commercial Relationships   David Wright, Spouse - Novartis (R), Spouse - Optos (R), Spouse - Roche (R); Evgenia Konstantakopoulou, None; Giovanni Montesano, None; Neil Nathwani, None; Anurag Garg, None; David Garway-Heath, None; David Crabb, Allergan (F), Allergan (R), Bayer (R), Santen (F), Santen (R), Thea (R); Gus Gazzard, None
  • Footnotes
    Support  National Institute for Health Research Health Technology Assessment Panel (09/104/40); MRC Innovation Fellowship (MR/S003770/1).
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 1438. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David Michael Wright, Evgenia Konstantakopoulou, Giovanni Montesano, Neil Nathwani, Anurag Garg, David F Garway-Heath, David P. Crabb, Gus Gazzard; Visual Field Outcomes from LiGHT: Laser in Glaucoma and Ocular Hypertension, a multicentre, randomised controlled trial.. Invest. Ophthalmol. Vis. Sci. 2020;61(7):1438.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : A recent report from the Laser in Glaucoma and Ocular Hypertension (LiGHT) trial showed that selective laser trabeculoplasty (SLT) provides better clinical effectiveness and lower treatment intensity among newly diagnosed glaucoma and ocular hypertension (OHT) patients compared to intra-ocular pressure lowering eye drops. The purpose of this secondary analysis of LiGHT data was to compare visual field outcomes of OHT and glaucoma patients treated with Medicine-1st against those treated with SLT (Laser-1st).

Methods : Visual fields (VFs) for 344 patients (588 eyes) treated with Medicine-1st and 344 patients (590 eyes) treated with Laser-1st were measured using standard automated perimetry and arranged in series (median length and duration: 9 VFs over 48 months). Hierarchical linear models were used to estimate pointwise VF progression rates, which were then averaged to produce a global progression estimate for each eye. Outcome measures were pointwise and global progression rates of total deviation (TD) and pattern deviation (PD). Proportions of points and patients in each treatment group with fast (< -1 dB/y) or moderate (< -0.5 dB/y) progression were compared using log-binomial regression.

Results : A greater proportion of eyes underwent moderate or fast TD progression in the Medicine-1st group compared with the Laser-1st group (26.2% vs. 16.9%; Risk Ratio, RR = 1.55 [1.23, 1.93], P < 0.001). A similar pattern was observed for pointwise rates (Medicine-1st 26.1% vs. Laser-1st 19.0%, RR = 1.37 [1.33, 1.42], P < 0.001). A greater proportion of pointwise PD rates were categorised as moderate or fast in the Medicine-1st group (Medicine-1st 11.5% vs. Laser-1st 8.3%, RR = 1.39 [1.32, 1.46], P < 0.001). Evidence for a difference in the proportion of eyes that underwent moderate or fast PD progression was weaker (Medicine-1st 9.9% vs. Laser-1st 7.1%, RR = 1.39 [0.95, 2.03], P = 0.0928).

Conclusions : Ocular hypertensive and glaucoma patients treated with Medicine-1st were more likely to undergo rapid VF progression than those treated with Laser-1st.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×